Genovate Biotechnology Co Ltd (4130) - Total Liabilities
Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has total liabilities worth NT$126.05 Million TWD (≈ $3.97 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Genovate Biotechnology Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Genovate Biotechnology Co Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Genovate Biotechnology Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
Genovate Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gandhi Special Tubes Limited
NSE:GANDHITUBE
|
India | Rs241.06 Million |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
Korea | ₩196.43 Billion |
|
Organic Tea Cosmetics Holdings Company Limited
KQ:900300
|
Korea | ₩73.67 Billion |
|
MFS High Income Municipal Closed Fund
NYSE:CXE
|
USA | $83.53 Million |
|
Afyon Cimento Sanayi TAS
IS:AFYON
|
Turkey | TL1.11 Billion |
|
Crest Ventures Limited
NSE:CREST
|
India | Rs4.03 Billion |
|
Mangata Holding S.A.
WAR:MGT
|
Poland | zł357.91 Million |
|
e-Credible Co. Ltd
KQ:092130
|
Korea | ₩22.81 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Genovate Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Genovate Biotechnology Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genovate Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual total liabilities of Genovate Biotechnology Co Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$126.05 Million ≈ $3.97 Million |
-10.65% |
| 2024-12-31 | NT$141.08 Million ≈ $4.44 Million |
+7.13% |
| 2023-12-31 | NT$131.69 Million ≈ $4.15 Million |
-14.27% |
| 2022-12-31 | NT$153.60 Million ≈ $4.84 Million |
+12.41% |
| 2021-12-31 | NT$136.65 Million ≈ $4.31 Million |
-5.67% |
| 2020-12-31 | NT$144.87 Million ≈ $4.56 Million |
-12.03% |
| 2019-12-31 | NT$164.68 Million ≈ $5.19 Million |
-4.43% |
| 2018-12-31 | NT$172.32 Million ≈ $5.43 Million |
-61.02% |
| 2017-12-31 | NT$442.06 Million ≈ $13.93 Million |
+11.34% |
| 2016-12-31 | NT$397.04 Million ≈ $12.51 Million |
+1.04% |
| 2015-12-31 | NT$392.95 Million ≈ $12.38 Million |
-- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more